Full Product Description
Ultima-Follistion 344 1mg is a cutting-edge peptide designed for athletes, bodybuilders, and fitness enthusiasts seeking natural muscle growth and improved strength. Derived from FST344, a specific isoform of follistatin, this peptide directly antagonizes myostatin (GDF-8), the protein responsible for limiting muscle development. By inhibiting myostatin, Ultima-Follistion 344 encourages significant increases in muscle mass, lean body composition, and strength.
Key Features:
-
Pure FST344 peptide (1mg per vial)
-
Myostatin antagonist to support muscle growth
-
Enhances strength, lean mass, and recovery
-
Easy integration into stacking protocols
-
Discreet shipping without brand labels for privacy
Ingredients:
-
Follistatin 344 (FST344) – the active peptide isoform
-
Sterile water for injection (as diluent)
Benefits:
-
Stimulates muscle growth by inhibiting myostatin
-
Promotes lean muscle mass and overall body strength
-
Supports quicker recovery after workouts
-
May enhance endurance and physical performance
-
Safe, research-backed peptide therapy
Recommended Usage:
-
Reconstitute per vial instructions with sterile water
-
Administer via subcutaneous or intramuscular injection
-
Typical dosage: 50–100 mcg daily, adjusted based on body weight and stacking protocol
-
Use cycles of 4–8 weeks, followed by a rest period
Stacking Options:
-
Stack with peptides like IGF-1 LR3 or GHRP/GHRH analogs for synergistic muscle gains
-
Can complement anabolic or hypertrophy-focused cycles
Safety and Precautions:
-
Use under supervision if you have underlying health conditions
-
Avoid if pregnant, breastfeeding, or under 18 years old
-
Store refrigerated (2–8°C) and protect from light
-
Always follow reconstitution and dosing guidelines for safety
Why Buy From Us:
-
Guaranteed high-quality, lab-tested FST344 peptide
-
Secure, discrete packaging for complete privacy
-
Fast international shipping and excellent customer support
-
Trusted supplier with consistent purity and potency






Reviews
There are no reviews yet.